Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Clinical trial NCT01089595 · TERMINATED
Trial details
- NCT number
- NCT01089595
- Sponsor
- Fox Chase Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2011-11-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.